Things are looking better all the time...
Please do not tell zab.
Dean Philips is a viable Democrat for President. If he could win the nomination, he would win against Trump. There are many of us who do not want Biden nor Trump--but Biden has failed at controlling the border and has presided over an inflationary environment that is making it difficult to overlook by the average voter.
BTW-- I was called by a pollster and I did not say I would vote for Trump in the primary. Makes me wonder how many who are polled if they say who they would really support.
Philips vs. Trump?
I would vote Philips.
fuagf-- Spare me and any others that do not agree with the Leftist posters here. We post a different point of view and we get attacked. No more posts stating what I believe. Just posting other points of view and perspective. So, there is no need for anyone to reply to my posts (You must admit that the board is more interesting and entertaining when you guys have me as a foil for the BS swill you call "economic theory". Or "woke culture" as an improvement for society etc.
Credit Card debt----Biden's economic plan?
Ah, yes. I keep on forgetting that deficit spending is not a problem for many. But PLEASE do not consider spending as a barometer of a healthy economy.
The voters responding to pollsters are telling how they feel. And they do not feel confident and secure of the future.
Who is going to win the Dem's coming Civil War?
What side are YOU on?
Ms. Cackle or Mr. Slickhead?
Until CUBT moves to a higher exchange and gets news out on any progress (most probably they owe money to clinical trial participants/CRO etc. and therefor cannot use any trial results until they pay).
It is sad to see someone who has all or most of their invest-able funds in one penny stock. No wonder there is such a focus that prompts frequent repetitive posting.
Wishing you all the best.
The Investment contemplates the issuance of up to 24,727,361 common shares of Versus to CECG representing approximately 51% of the Company’s issued and outstanding common shares of which 15,838,441 common shares (the “First Tranche) were issued to CECG on November 22, 2023 and a further 8,888,920 common shares (the “Second Tranche”) are expected to be issued to CECG next week.
Per the terms of the agreement, CECG purchased the First Tranche at a price of $0.1618 per share, representing a premium to the five-day average Nasdaq Official Closing Price of $0.1578 per share, for a total USD $2,562,659.76. The Second Tranche will be completed at the same price per share.